Cargando…
32688 Evaluation of demographics for patients on immunomodulatory therapy during the COVID-19 pandemic
Autores principales: | Gibson, Ruby S., Santillan, Monica Rosales, Porter, Martina L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Mosby, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465208/ http://dx.doi.org/10.1016/j.jaad.2022.06.693 |
Ejemplares similares
-
Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy
por: Holcomb, Zachary E., et al.
Publicado: (2020) -
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients
por: Giossi, Riccardo, et al.
Publicado: (2021) -
Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic
por: Shah, Payal, et al.
Publicado: (2020) -
Immunomodulatory therapies for COVID-19
por: Mathur, Poonam, et al.
Publicado: (2022) -
Fasting Ramadan During COVID-19 Pandemic: Immunomodulatory Effect
por: Abunada, Taghreed, et al.
Publicado: (2020)